跳转至内容
Merck

SML0506

Sigma-Aldrich

LY-411575

≥97% (HPLC)

别名:

LSN-411575, LY 411575, N2-[(2S)-2-(3,5-二氟苯基)-2-羟基乙酰]-N1-[(7S)-5-甲基-6-氧代-6,7-二氢-5H-二苯并[b,d]氮杂-7-基]-L-丙氨酰胺

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C26H23F2N3O4
分子量:
479.48
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

化驗

≥97% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 5 mg/mL, clear

運輸包裝

wet ice

儲存溫度

−20°C

SMILES 字串

C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@@H]2C(=O)N(C)c3ccccc3-c4ccccc24

InChI

1S/C26H23F2N3O4/c1-14(29-25(34)23(32)15-11-16(27)13-17(28)12-15)24(33)30-22-20-9-4-3-7-18(20)19-8-5-6-10-21(19)31(2)26(22)35/h3-14,22-23,32H,1-2H3,(H,29,34)(H,30,33)/t14-,22-,23-/m0/s1

InChI 密鑰

ULSSJYNJIZWPSB-CVRXJBIPSA-N

應用

LY-411575已被用作有效的γ-分泌酶抑制剂和Notch抑制剂。

生化/生理作用

LY-411575是一种有效的细胞渗透性和选择性γ-分泌酶抑制剂,可在急性或慢性治疗后降低Aβ/42,并阻断Notch活化。研究(癌细胞)已显示用LSN-411575治疗可通过抑制HES1表达和ERK磷酸化,阻滞KrasG12V驱动的NSCLC。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Enzymatic assays for studying intramembrane proteolysis.
Bolduc D M, et al.
Methods in Enzymology, 584, 295-308 (2017)
Prion-protein-interacting amyloid-β oligomers of high molecular weight are tightly correlated with memory impairment in multiple Alzheimer mouse models.
Kostylev M A, et al.
The Journal of Biological Chemistry, 290(28), 17415-17438 (2015)
K Pandya et al.
British journal of cancer, 105(6), 796-806 (2011-08-19)
We reported that Notch-1, a potent breast oncogene, is activated in response to trastuzumab and contributes to trastuzumab resistance in vitro. We sought to determine the preclinical benefit of combining a Notch inhibitor (γ-secretase inhibitor (GSI)) and trastuzumab in both
Different developmental histories of beta-cells generate functional and proliferative heterogeneity during islet growth.
Singh S P, et al.
Nature Communications, 8(1), 664-664 (2017)
Kyung-Won Park et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 29(7), 2294-2307 (2021-03-02)
Numerous aggregation inhibitors have been developed with the goal of blocking or reversing toxic amyloid formation in vivo. Previous studies have used short peptide inhibitors targeting different amyloid β (Aβ) amyloidogenic regions to prevent aggregation. Despite the specificity that can be

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门